(Total Views: 316)
Posted On: 07/08/2019 8:25:45 AM
Post# of 54
$CBIO News Article - Catalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bleeding Rate in the Phase 2 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Patients with Hemophilia A or B with Inhibitors https://marketwirenews.com/news-releases/cata...65263.html
(0)
(0)
My Twitter: WhyteStocks
